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Inhaled methoxyflurane and intranasal fentanyl for
prehospital management of visceral pain in an
Australian ambulance service
Steven Johnston,1,2 Garry J Wilkes,1,2,3 Jennifer A Thompson,4 Mel Ziman,4
Richard Brightwell1,2
ABSTRACT
Objective This study analysed the analgesic effect and
changes in vital signs associated with administration of
inhaled Methoxyflurane (MTX) and/or intranasal Fentanyl
(INF) for prehospital management of visceral pain.
Method A retrospective, observational study reviewing
1024 randomly selected records of patients with
presumed visceral pain administered MTX (465), INF
(397) or both (162) by the Western Australian
Ambulance Service between January 2004 and February
2006. Clinical variables assessed included systolic blood
pressure, pulse rate, respiration rate and Glasgow Coma
Scale score. Pain was assessed utilising Visual/Verbal
Analogue Scale pain scores.
Results Overall effects on vital signs appeared
favourable 5 min after use and at hospital arrival with
either agent alone or in combination. As sole agents,
MTX produced the greatest initial pain scores reduction
(2.0 (1.7 to 2.2) vs 1.6 (1.4 to 1.8)) (mean (95% CI), and
INF provided greater pain reduction by hospital arrival
(3.2 (2.9 to 3.5) vs 2.5 (2.1 to 2.9)). While both agents
were effective, INF provided a greater pain score
reduction for cardiac (3.0 (2.6 to 3.4) vs 2.3 (1.8 to 2.8)),
female (3.4 (2.9 to 4.0) v 2.5 (2.0 to 3.0)) and age 75+
patients (3.2 (2.5 to 3.8) vs 1.8 (1.0 to 2.5)). Combined
use of agents was not advantageous.
Conclusions MTX and INF are effective agents for
providing visceral pain analgesia in the prehospital
setting. While MTX provided a more rapid onset of pain
relief, INF provided superior analgesia after subsequent
doses and in female, cardiac and older patients.
INTRODUCTION
A variety of prehospital analgesic agents have been
used by emergency care practitioners for many
years, but they share the common feature of
paucity of literature regarding safety, efficacy and
relative efficiency.1
In Australia, the most frequently used analgesic
agent in ambulance practice is Methoxyflurane
(MTX), administered by First Aid, Volunteer and
Paramedic Ambulance personnel. Opioids are
authorised for use by all paramedics in some
services and selected officers in others. In Western
Australia all paramedics are also authorised to
administer intranasal Fentanyl (INF) and its use is
increasing across ambulance services in Australia.
INF is becoming increasingly popular in paediatric
emergency medicine in Australasia in preference to
intravenous Morphine.2 3
Although these agents are well established in
local ambulance and military practice, they are not
widely used elsewhere in the world with few
reports regarding efficacy and safety.4 5 The aim of
this study was to analyse the analgesic effect and
changes in vital signs associated with administra-
tion of MTX and INF in the prehospital manage-
ment of pain of presumed visceral origin in Western
Australia, and to explore whether combined use is
advantageous.
MTX is a volatile, fluorinated hydrocarbon used
for analgesia in paediatric and adult patients since
the 1960s.6 Reports have questioned its safety due
to dose-dependent nephrotoxicity for longer-term
analgesia7 and anaesthesia,8 particularly when used
in conjunction with known nephrotoxins.9 MTX
has been used routinely in subanaesthetic doses by
ambulance services Australia-wide for prehospital
analgesia for more than three decades at doses
lower than those reported above where adverse
events have been observed. The Therapeutic Goods
Administration (TGA) has no reports of renal
toxicity despite an estimated three million patient
treatments (Medical Developments International,
personal communication 2009). Small observa-
tional studies report it as a safe and reliable
prehospital analgesic when used at analgesic doses
for both adult10 and paediatric patients, with the
caveat that it may lead to brief, self-limiting
episodes of deep sedation in young children.11 12
Longer-term follow-up of more than 17 000
patients receiving MTX has shown no increase in
adverse events (I Jacobs, unpublished data 2009).
Exposure to anaesthetic gases is measured in
parts per million (ppm). Thresholds are described as
a time-weighted average (TWA) (the average
continuous exposure) and a ‘ceiling’ level over
a single hour, generally cited as four times the
TWA.13
Exposure Standards have not been established for
MTX. Standards for Halothane are accepted as
applicable and relevant. The TWA threshold for
Halothane as a sole agent (and hence MTX) is
50 ppm.14 However, in the operating room envi-
ronment, Halothane is typically administered with
nitrous oxide (N2O) at 50 times the concentration
of Halothane. The TWA for N2O is 25 ppm. Hence,
in the operating room environment, the TWA for
Halothane is adjusted to 0.5 ppm (and ceiling value
2 ppm) because, although this is 100 times lower
than the threshold value for Halothane itself, a level
of Halothane of 0.5 ppm would be associated with
N2O at its threshold level of 25 ppm.
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An Ambulance commissioned study of MTX exposure found
that MTX levels did not reach the 1 h peak of 2 ppm or shift
average of 0.5 ppm unless oxygen was administered through the
device.15 Ambulance Services throughout Australia have now
changed Practice Guidelines to advise against routine adminis-
tration of oxygen through the device (see online appendix).
Fentanyl is a potent, synthetic opioid used for analgesia since
the 1960s.16 Previous studies favourably report its safety and
efficacy as a prehospital analgesic in both paediatric and adult
cases when administered intravenously17e22 or intranasally.3 23
Fentanyl has been suggested as the preferred opioid in the
prehospital setting19 due to its rapid pain relief, short duration of
action, non-histamine release (a major component contributing
to hypotension) and reduced incidence of nausea and
vomiting.16 21 24 When compared for efficacy in the prehospital
setting, INF and intravenous morphine are comparable.23
Within the Western Australian Ambulance Service, the most
commonly used analgesic agents are inhaled MTX, introduced in
the 1980s and INF introduced in 2001. Combined use has been
reported by paramedics to enhance pain relief. This reported
synergism, however, remains to be verified.
METHODS
We undertook a retrospective, observational review of patient
care record forms encompassing patients administered MTX or
INF for the prehospital management of presumed visceral pain
by the Western Australian Ambulance Service between January
2004 and February 2006. For the purpose of this study, visceral
pain was determined by attending paramedics as being of
cardiac, renal or abdominal aetiology.
Of 14 232 cases available, 10 900 (76.6%) patients received
MTX, and 3332 (23.4%) patients received INF. Six hundred cases
were randomly selected per drug cohort, with cases coded as
abdominal, renal or cardiac pain. One thousand and twenty-four
cases had sufficient data for further analysis. Of these, 465
(45.4%) received MTX, 397 (38.8%) received INF, and 162
(15.8%) received both.
MTX is self-administered by patients via a hand-held inhala-
tion device (Penthrox inhaler; Medical Developments Interna-
tional, Springvale, Australia). A single dose of 3 ml delivers MTX
at a concentration of 0.2% or 0.4% depending on whether the
diluter hole is open or occluded. After an initial loading dose of
10e12 breaths through the device, the patient is encouraged to
take a few breaths through the device every few minutes as
required thereafter. A single dose will provide analgesia for
15e20 min if oxygen is administered through the device, or up
to 1 h if used intermittently (and oxygen administered sepa-
rately by face mask as required). A second dose may be admin-
istered when the initial dose has been exhausted.
INF was administered by attending ambulance officers via
a metered dose delivery at a concentration of 300 mg/ml in
accordance with the dosing regimen in table 1.
The choice of analgesic agent is at the discretion of the
attending paramedic. For both agents, administration is
continued as needed up to hospital arrival and may be continued
at the discretion of receiving hospital staff.
Data extracted from patient records included patient demo-
graphics (age, gender, aetiology of pain), vital signs (systolic
blood pressure (SBP), pulse rate, respiration rate and Glasgow
Coma Scale (GCS) score), and a pain assessment utilising Visual/
Verbal Analogue Scale (VAS) pain scores (assessed by para-
medics). The limits used to define clinically significant extremes
of vital sign measurements are listed in table 2. A 1.4-point
change in VAS pain score is considered clinically significant.25 As
VAS pain scores for individual patients are assessed as whole
numbers, a change of 2 points was considered clinically signifi-
cant for an individual patient.
Statistics
Data were exported into and analysed with SPSS (version 11.5:
SPSS, Chicago, Illinois). Descriptive statistics and frequencies are
reported. A sample size of 600 per drug cohort was calculated to
provide 80% power to detect a statistical difference with a set at
0.05. A two-way, repeated-measures analysis of variance
(ANOVA) was used to test for significant differences in vital sign
means over the measured intervals. The Student t test was used
to compare pain score reduction and c2 test for proportions with
pain score reduction $2 points.
RESULTS
Patient demographics
Males (584) represented 57% of the cohort, and most patients
(62.3%) were over 50 years of age with a mean age of 59.1
(female 58.7, male 59.4) years (table 3). Pain aetiology was
classified by the attending paramedic as cardiac (485, 47.4%),
abdominal (249, 24.3%) and renal (290, 28.3%) (table 4).
Physiological vital signs
SBP, pulse rate and respiration rate were recorded at three time
points: prior to administration of medication, 5 min after
administration and on arrival at hospital. Changes in conscious
state were assessed by determining GCS prior to and 5 min after
administration of the analgesic agent.
Blood pressure
Changes in SBP 5 min after initial analgesic dose varied consid-
erably for individual patients (range 170 mm Hg to +70 mm
Hg). Despite these large individual variations, the majority of
changes were towards the normal range. Only four patients
with initial SBP>100 mm Hg entered the hypotensive range
(SBP<90 mm Hg). Three received INF as sole therapy for cardiac
pain, and one patient received both for abdominal pain.
The reduction in mean SBP 5 min after the initial dose of
MTX was 5.7 mm Hg (median 10 mm Hg) and after INF was
4.5 mm Hg (median 5 mm Hg) (table 5). Similar changes were
seen on arrival at hospital, with MTX reducing mean SBP by
15.1 mm Hg (median 20 mm Hg) and INF 11.5 mm Hg (median
15 mm Hg).
Table 1 Intranasal fentanyl dose regimen
Dose chart
Age First dose Subsequent at 10 min
<5 years <20 kg 130.05 ml (15 mg) 130.05 ml (15 mg)
6e10 years 21e30 kg 130.10 ml (30 mg) 130.10 ml (30 mg)
Subsequent at 5 min
11e15 years 31e40 kg 130.15 ml (45 mg) 130.15 ml (45 mg)
Small/elderly/frail 230.20 ml (120 mg) 130.20 ml (60 mg)
Adult 330.20 ml (180 mg) 130.20 ml (60 mg)
Table 2 Vital sign parameters classified as clinically significant
Vital sign Lower limit Upper limit
Systolic blood pressure (mm Hg) <90 (hypotension) >180 (hypertension)
Pulse rate (per min) <60 (bradycardia) >100 (tachycardia)
Respiration rate (per min) <8 (bradypnoea) >24 (tachypnoea)
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On hospital arrival, 10 patients with initial SBP>100 mm Hg
had entered the hypotensive range. All received INF, nine with
cardiac and one abdominal pain. MTX was also administered to
the abdominal pain and two of the cardiac pain patients. None
of these patients received nitrates or other cardiac medications.
Of those who became hypotensive after treatment, no other
adverse effects in physiological parameters and no fall in GCS
were noted. One patient increased SBP within the hypertensive
range after treatment (SBP rise from 180 to 190 mm Hg).
Pulse rate
Pulse rate changes were minimal (table 5). In the majority of
cases, both agents affected pulse rate favourably towards normal
values, but changes were not significant for either cohort.
Respiratory rate
Assessment of respiration indicated very little effect after
administration of either agent (table 5). Overall, mean respira-
tion declined by 1.7 rpm initially and by 2.1 rpm on hospital
arrival, with median respiration rates unchanged. No patients
became bradypnoeic.
GCS
Changes in GCS were negligible (table 6). Five patients had falls
in GCS (maximum two points in a male with renal pain
receiving INF), and four patients had increased GCS (maximum
four points).
Pain scores
Pain score reduction by VAS was assessed 5 min after treatment
and on arrival at hospital (table 7). A further subgroup analysis
by agent, gender, aetiology and pain group was also performed
(table 8). Transport times were comparable for both agents.
As sole agents, MTX produced the greatest initial pain score
reduction (p¼0.452), and INF provided greater pain reduction by
hospital arrival (p¼0.007). While both agents were effective, INF
provided a significantly greater pain score reduction for cardiac
(p¼0.025), female (p¼0.020) and age 75+ patients (p¼0.006) on
arrival at hospital.
Analysis of the proportion of individual patients achieving
pain score reductions of two points or greater by hospital arrival
showed significantly higher proportions with INF overall
(p¼0.027) and for the subgroups of cardiac aetiology (p¼0.033),
female patients (p¼0.021), female patients with cardiac aeti-
ology (p¼0.044) and for patients aged 45e59 years (p¼0.047).
Further analysis of the patients aged 75+ years with cardiac
pain showed that the difference between agents was limited to
female patients in this subgroup (p¼0.003) where MTX
appeared to be ineffective (table 8).
Differences in pain score between agents were seen in the
age groups <30 years (1.50 reduction), 75+ years (1.41 reduc-
tion) and in the subgroup of patients with cardiac pain and aged
75+ years (males 1.16, females 1.99, overall 1.95).
The patient care records in use at the time of the study did not
record which agent was administered first, and so this could not
be analysed. Combined use of agents was not advantageous.
For the 465 patients administered MTX, a single 3 ml dose
was used in 241 patients (51.9%), a second dose was used in 195
patients (41.9%) and 29 (6.2%) received a third dose. The mean
total dose of INF administered per patient was 362 mg (median
240 mg; SD6191.74).
DISCUSSION
The objective of this study was to analyse and compare the
analgesic effect and changes in vital signs associated with
administration of MTX and/or INF for the prehospital
management of visceral pain. Both agents proved effective with
no bradypnoea.
Only one case increased SBP within the hypertensive range
(increase from 180 to 190 mm Hg) which is unlikely to be
clinically significant. All cases that experienced a fall in SBP
from >100 mm Hg to hypotensive levels received INF either
alone or in combination with MTX. However, these patients did
not experience any fall in GCS or other evidence of respiratory or
cardiovascular compromise. The results concur with previous
studies indicating that INF is an agent with good analgesic
properties.2 26e28 While one small study found that the rate of
adverse events for patients treated with INF in a prehospital
Table 3 Age group, gender and agent administered
Gender and agent
Gender unspecified Female Male
Age group (years) Fentanyl Methoxy Fentanyl Both Female total Methoxy Fentanyl Both Male total Grand total
0 to 29 27 9 6 42 16 11 27 69
30 to 44 1 70 32 16 118 64 27 28 119 238
45 to 59 61 32 15 108 56 61 51 168 276
60 to 74 1 32 40 9 81 72 81 30 183 265
75+ 2 36 49 2 87 29 51 5 85 174
Unspecified 2 2 2
Grand total 4 226 162 48 436 239 231 114 584 1024
Table 4 Aetiology, gender and agent administered
Gender and agent
Gender unspecified Female
Female total
Male
Male total Grand totalAetiology Fentanyl Methoxy Fentanyl Both Methoxy Fentanyl Both
Abdominal 1 61 52 32 145 37 37 29 103 249
Cardiac 3 107 99 3 209 97 159 17 273 485
Renal 58 11 13 82 105 35 68 208 290
Grand total 4 226 162 48 436 239 231 114 584 1024
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setting was more than double that of patients administered
with intravenous morphine, these effects were minor and did
not reach statistical significance.23
MTX as a sole agent was not associated with any adverse
physiological effects.
The results of the current study of prehospital MTX and INF
indicate both provide effective pain relief. MTX showed
a greater pain reduction 5 min after commencement of treat-
ment. INF showed a superior pain reduction on arrival at
hospital. The results of this study concur with studies
conducted in a hospital environment, which report a mean
reduction in VAS pain score of approximately four points.29 30
The time course of VAS pain score reduction we observed is
similar to that in hospital for paediatric patients (1.67 point
reduction 10 min postadministration and 2.91 point reduction
30 min postadministration).31
The subgroup analysis shows that both agents provide effec-
tive analgesia across the range of age, gender and pain aetiology.
INF produced greater increases in pain score reduction and
proportion of patients with VAS reduction of two or more in the
subgroups of cardiac pain, female patients and age 75 years and
above on arrival at hospital.
It is reassuring to note that for cardiac aetiology of pain,
neither INF nor MTX caused respiratory depression or adverse
pulse rate changes. INF administration demonstrated more
effective pain relief in this group but was also associated with
a small number of cases developing hypotension. These
effects do not appear to have been associated with clinical
compromise and are reassuring in this particular group who are
at greatest risk of cardiovascular compromise from analgesic
agents.
This study has demonstrated similar results to that seen when
morphine was compared with the fentanyl derivative alfentanil
for relief of acute ischaemic-type chest pain in the prehospital
environment.32 More rapid pain relief from alfentanil was noted
15 min after administration. However, while INF provided
greater pain relief at arrival at hospital, it is evident that MTX is
also an effective analgesic agent. Further analysis of the cardiac
patients aged 75 years and above showed INF to be particularly
effective and MTX ineffective in this group. However, the actual
numbers are small, and caution is advised on interpretation of
this result.
Historical analysis of INF dosage administration by St John
Ambulance paramedics in Western Australia demonstrates
a substantial increase in dose per patient since its introduction in
2001, with the average administration increasing from 180 mg in
the initial stages following introduction of the agent (Ford D,
unpublished, 2004) to the mean reported here of 362 mg.
Following analysis of the pilot period in 2001, the initial dose for
adults was increased in 2002 from 120 mg to 180 mg, and ongoing
education has reinforced the need to continue administration at
the recommended intervals if pain relief is inadequate. Increased
experience and comfort with use have also contributed to this
increase in total dose per person observed over time. The
increased total dose administered per patient since initial use in
2001 to that observed here in 2004, without significant adverse
effects, is most likely reflective of previously inadequate doses.
This ‘oligoanalgesia’ is well recognised in the prehospital
setting.33e35
It should be noted that as the population examined in this
study were suffering from visceral pain, they are therefore
physiologically distinct from patients with pain of traumatic
origin, which has been more extensively studied. This may
explain the difference between previous findings of a four-point Ta
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pain reduction for traumatic pain (Ford, unpublished, 2004)
compared with a three-point reduction found in this study of
visceral pain.36e38
The use of MTX has changed since the time of this study.
Previously, it was routine practice to administer oxygen through
the device. This is now recognised to increase evaporation of the
agent into the ambient air, reducing the dose delivered to the
patient and limiting analgesia to 15e20 min. The current
recommended technique is to administer oxygen via a separate
face mask and not through the inhaler (see online appendix).
Intermittent use of MTX in this manner allows a single dose to
last approximately 1 h, and as a result, the need to refill the
inhaler with a second dose is now exceedingly uncommon. The
briefer duration of effect with oxygen administered through the
devicedwhich was common at the time of the studydmay also
contribute to the lesser effect of MTX with longer transports
and by hospital arrival despite having a greater initial effect.
With oxygen flowing through the device, exhaustion of the
MTX may not have been apparent to either patient or treating
officer and hence analgesic effect removed. Further analysis with
the current technique and/or comparison of techniques may
yield more information.
Interestingly, there was no significant difference in pain
assessment scores of patients who received MTX and INF in
combination, relative to INF alone. This is consistent with
a previous study23 that demonstrated similar or less pain
reduction when these agents were combined in patients with
non-cardiac pain. One possible explanation is that a second
agent has been used when the first agent is ineffective, and
hence the use of both agents is apparently less as it is a group of
relative ‘non-responders’ or those suffering hyperalgesia. Further
studies will be required to examine the sequence and timing of
agents and the effect of each individually when used in combi-
nation. It is also unknown how frequently both agents were
used simultaneously from the outset. Until these issues are
clarified, no firm recommendations can be made regarding
routine use of both agents.
Limitations
The limitations of the study are consistent with retrospective,
observational studies of this nature and relate to available
equipment, the study population and compliance with recording
procedures.
The investigation of the analgesic agents’ effect on respiration
has been limited to respiratory rate and GCS. More sensitive
indicators are oxygen saturation and end tidal CO2 (ETCO2)
monitoring. However, oxygen saturations were not routinely
measured and/or repeated at the time of this study and ETCO2
monitoring in spontaneously breathing patients requires Ta
bl
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2)Table 6 Glasgow Coma Scale before and after treatment
Glasgow Coma
Scale before agent
Agent
Glasgow Coma
Scale after agent 15 14 13 12 11 Grand total
Methoxy 15 456 2 1 459
14 1 2 3
Fentanyl 15 380 1 381
14 2 3 5
13 1 1
12 1 1
Both 15 156 156
14 3 3
Grand total 996 11 1 1 1009
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equipment not currently utilised in ambulance services in
Australia. It is possible, therefore, that minor degrees of respi-
ratory depression have not been identified. Similarly, GCS is
a crude estimate of conscious status. Confusion and/or disori-
entation are important effects produced by both these agents
but not specifically analysed in this study. Further research is
required to assess the significance or otherwise of these factors.
No allowance has been made for the analgesic effect of
nitrates and oxygen for patients with pain of presumed cardiac
origin. Although the use of these confounders is routine and is
assumed to be similar between subgroups, this was not specifi-
cally analysed. Similarly, the pathological conditions associated
with visceral pain influence the physiological parameters
measured making interpretation of changes difficult to deter-
mine because of pain, pain relief, underlying condition or
combinations of these.
While the study population encompassed all age groups, only
1.1% of patients were under 20 years of age. Paediatric patients
are therefore under-represented in this study, and as such we are
unable to specifically analyse the effects in this group. Finally,
the analysis of patient records was hampered by incomplete
data, with missing values attributed to short journey time to
hospital and non-compliance with completion of the case sheets
by paramedics.
CONCLUSION
The results presented in this paper demonstrate MTX and INF
are effective analgesic agents for the prehospital management of
visceral pain, with only a very small number of cases in the INF
group associated with subsequent hypotension but no change in
GCS or other evidence of cardiovascular compromise. No
patients were compromised by a fall in consciousness level or
impaired respiratory rate. MTX may be the treatment of choice
for shorter patient contact cases due to ease of administration,
but INF provided superior pain relief at hospital arrival, and
achieved greater pain relief for presumed cardiac pain, particu-
larly in older and female patients. No clinical advantage could be
detected by their combined use, however measures were limited.
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